Strides Pharma Science Limited has announced that its step-down subsidiary, Strides Pharma International AG, has entered into definitive agreements with Sandoz AG and its affiliates to acquire and in-license a portfolio of branded generic pharmaceutical products across Sub-Saharan Africa. The transaction covers four key markets, including a regional cluster in Western Africa spanning 10 countries, as well as Ghana, Nigeria and Kenya. The portfolio comprises established brands across therapeutic areas such as anti-infectives, cardiovascular treatments and dermatology. Several of these products generate annual revenues exceeding US$1 million, reflecting strong market presence and physician acceptance.
Under the agreement, Strides will fully acquire selected products while continuing to market others on behalf of Sandoz. To ensure uninterrupted supply, the companies will also enter into a manufacturing and supply arrangement, enabling continued production of these medicines.
The acquisition is expected to significantly strengthen Strides’ footprint in Sub-Saharan Africa, positioning the company among the top pharmaceutical players in the region by sales. The expanded portfolio is anticipated to enhance market coverage, deepen therapeutic offerings and improve engagement with healthcare providers.
The integration of Sandoz’s branded products with Strides’ existing operations is expected to create multiple strategic benefits. These include broader access to prescribers, pharmacies and healthcare institutions, as well as opportunities for cross-selling across an expanded product range. The combined portfolio is also expected to strengthen the company’s credibility and visibility in key markets.
The transaction involves an upfront consideration of US$12 million, to be funded through internal resources. It is expected to contribute positively to earnings, supported by the profitability of the acquired brands and operational efficiencies from a larger commercial platform. Completion of the transaction is anticipated by the end of the second quarter of FY27, subject to regulatory approvals and customary closing conditions.
Company leadership highlighted the deal as a key step in advancing its long-term growth strategy in Africa, where demand for accessible and affordable healthcare solutions continues to rise. The expansion aligns with the company’s focus on building a strong presence in emerging markets alongside its operations in regulated regions.
Strides Pharma Science Limited is a global pharmaceutical company headquartered in Bengaluru, India, with operations spanning over 100 countries. The company operates manufacturing facilities in India, the United States, Italy and Kenya, and focuses on developing and supplying complex and difficult-to-manufacture pharmaceutical products across regulated and emerging markets.